Levetiracetam XR in Very Heavy Drinkers (NCIG 002)
This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
ClinicalTrials.gov Identifier:
NCT00970814
First received: September 1, 2009
Last updated: May 30, 2012
Last verified: May 2012
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
The primary objectives of this study are to assess the efficacy of levetiracetam XR in increasing the percentage of subjects with no heavy drinking days and in reducing the weekly percentage of heavy drinking days in subjects with alcohol dependence confirmed by DSM-IV criteria and who frequently consume 10 or more drinks per drinking day for men and 8 or more drinks per drinking day for women (designated as "very heavy" drinkers).
| Condition | Intervention | Phase |
|---|---|---|
|
Alcoholism |
Behavioral: BBCET Drug: Levetiracetam XR Drug: Sugar Pill |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A Phase 2, Double Blind, Placebo Controlled Trial to Assess the Efficacy Of Levetiracetam Extended Release in Very Heavy Drinkers |
Resource links provided by NLM:
MedlinePlus related topics:
Alcoholism
Drug Information available for:
Levetiracetam
U.S. FDA Resources
Further study details as provided by National Institute on Alcohol Abuse and Alcoholism (NIAAA):
Primary Outcome Measures:
- The Percentage of Subjects With no Heavy Drinking Days During Study Weeks 5 Through 14. [ Time Frame: Weeks 5-14 ] [ Designated as safety issue: No ]A heavy drinking day is 5+ drinks per day for men and 4+ drinks per day for women based on self report.
- The Weekly Percentage of Heavy Drinking Days During Study Weeks 5 Through 14. [ Time Frame: Study Weeks 5-14 ] [ Designated as safety issue: No ]A heavy drinking day is 5+ drinks per day for men and 4+ drinks per day for women based on self report.
Secondary Outcome Measures:
- The Number of Drinks Per Drinking Day Study Weeks 5-14. [ Time Frame: Study Weeks 5-14 ] [ Designated as safety issue: No ]based on self report
| Enrollment: | 130 |
| Study Start Date: | October 2009 |
| Study Completion Date: | October 2010 |
| Primary Completion Date: | August 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Levetiracetam XR
Group received Levetiracetam
|
Behavioral: BBCET
11 BBCET sessions
Drug: Levetiracetam XR
500mg - 2000mg Once per day 16 weeks
|
|
Placebo Comparator: Sugar Pill
Placebo
|
Behavioral: BBCET
11 BBCET Sessions
Drug: Sugar Pill
500mg - 2000mg Once per day 16 weeks
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- The subject must be at least 18 years of age.
- The subject must have a DSM-IV diagnosis of current alcohol dependence.
- The subject must be seeking treatment for alcohol dependence and desires a reduction or cessation of drinking.
- The subject must be able to verbalize understanding of the consent form, able to provide written informed consent, verbalize willingness to complete study procedures, able to understand written and oral instructions in English and able to complete the questionnaires required by the protocol.
If the subject is female and of child bearing potential, she must agree to use at least one of the following methods of birth control, or she must be surgically sterile or postmenopausal:
- oral contraceptives
- contraceptive sponge
- patch
- barrier (diaphragm or condom)
- intrauterine contraceptive system
- levonorgestrel implant
- medroxyprogesterone acetate contraceptive injection
- complete abstinence from sexual intercourse, and/or
- hormonal vaginal contraceptive ring.
- The subject must be able to take oral medication, willing to adhere to the medication regimen, and willing to return for regular visits.
- The subject must complete all psychological assessments required at screening and baseline.
- The subject must provide evidence of stable residence in the last 2 months prior to randomization, have reasonable transportation arrangements to the study site, and have no plans to move within the next 3 months or unresolved legal problems. Subjects must provide contact information of someone, such as a family member, spouse, or significant other, who may be able to contact the subject in case of a missed clinic appointment.
- The subject must have a breath alcohol concentration (BAC) equal to 0.000 when s/he signed the informed consent document.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00970814
Locations
| United States, Maryland | |
| Johns Hopkins School of Medicine | |
| Baltimore, Maryland, United States, 21224 | |
| United States, Massachusetts | |
| Boston University School of Medicine | |
| Boston, Massachusetts, United States, 02118 | |
| United States, New Hampshire | |
| Dartmouth Medical School | |
| Lebanon, New Hampshire, United States, 03755 | |
| United States, Pennsylvania | |
| University Of Pennsylvania | |
| Philadelphia, Pennsylvania, United States, 19104 | |
| United States, Virginia | |
| University of Virginia | |
| Charlottesville, Virginia, United States, 22911 | |
Sponsors and Collaborators
Investigators
| Principal Investigator: | Raye Z Litten, Ph.D. | National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
| Principal Investigator: | Margaret M Mattson, Ph.D. | National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
| Principal Investigator: | Joanne E Fertig, Ph.D. | National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
More Information
Publications:
| Responsible Party: | National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
| ClinicalTrials.gov Identifier: | NCT00970814 History of Changes |
| Other Study ID Numbers: | NIAAA_DTRR-2009-LITTEN-02 |
| Study First Received: | September 1, 2009 |
| Results First Received: | April 26, 2012 |
| Last Updated: | May 30, 2012 |
| Health Authority: | United States: Federal Government |
Keywords provided by National Institute on Alcohol Abuse and Alcoholism (NIAAA):
|
Alcoholism Alcohol Drinking Alcoholic Intoxication Alcohol Abuse |
Additional relevant MeSH terms:
|
Alcoholic Intoxication Alcoholism Alcohol-Related Disorders Substance-Related Disorders Mental Disorders Etiracetam Piracetam Anticonvulsants |
Central Nervous System Agents Therapeutic Uses Pharmacologic Actions Nootropic Agents Neuroprotective Agents Protective Agents Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on June 13, 2013